Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation

JCO Precis Oncol. 2022 Apr:6:e2100371. doi: 10.1200/PO.21.00371.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Astrocytoma* / drug therapy
  • Humans
  • Morpholines
  • Mutation
  • Pyrimidines / therapeutic use
  • Pyrroles
  • Receptor, Fibroblast Growth Factor, Type 1 / genetics

Substances

  • Morpholines
  • Pyrimidines
  • Pyrroles
  • FGFR1 protein, human
  • Receptor, Fibroblast Growth Factor, Type 1
  • pemigatinib